MedTrace Logo

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

NCT00483977 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2011-04-29

No results posted yet for this study

Summary

The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.

Conditions

Interventions

DRUG

Oxycodone

Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks

DRUG

Placebo

Placebo: oral for 2 weeks.

DRUG

PF-000592379

PF-00592379: oral, 30 mg, once a day for 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483977 on ClinicalTrials.gov